Differential molecular mechanistic behavior of HDACs in cancer progression

dc.contributor.authorSingh, Tashvinder
dc.contributor.authorKaur, Prabhsimran
dc.contributor.authorSingh, Paramdeep
dc.contributor.authorSingh, Sandeep
dc.contributor.authorMunshi, Anjana
dc.date.accessioned2024-01-21T10:54:07Z
dc.date.accessioned2024-08-14T07:40:52Z
dc.date.available2024-01-21T10:54:07Z
dc.date.available2024-08-14T07:40:52Z
dc.date.issued2022-08-16T00:00:00
dc.description.abstractGenetic aberration including mutation in oncogenes and tumor suppressor genes transforms normal cells into tumor cells. Epigenetic modifications work concertedly with genetic factors in controlling cancer development. Histone acetyltransferases (HATs), histone deacetylases (HDACs), DNA methyltransferases (DNMTs) and chromatin structure modifier are prospective epigenetic regulators. Specifically, HDACs are histone modifiers regulating the expression of genes implicated in cell survival, growth, apoptosis, and metabolism. The majority of HDACs are highly upregulated in cancer, whereas some have a varied function and expression in cancer progression. Distinct HDACs have a positive and negative role in controlling cancer progression. HDACs are also significantly involved in tumor cells acquiring metastatic and angiogenic potential in order to withstand the anti-tumor microenvironment. HDACs� role in modulating metabolic genes has also been associated with tumor development and survival. This review highlights and discusses the molecular mechanisms of HDACs by which they regulate cell survival, apoptosis, metastasis, invasion, stemness potential, angiogenesis, and epithelial to mesenchymal transitions (EMT) in tumor cells. HDACs are the potential target for anti-cancer drug development and various inhibitors have been developed and FDA approved for a variety of cancers. The primary HDAC inhibitors with proven anti-cancer efficacy have also been highlighted in this review. � 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.en_US
dc.identifier.doi10.1007/s12032-022-01770-4
dc.identifier.issn13570560
dc.identifier.urihttps://kr.cup.edu.in/handle/32116/4221
dc.identifier.urlhttps://link.springer.com/10.1007/s12032-022-01770-4
dc.language.isoen_USen_US
dc.publisherSpringeren_US
dc.subjectAngiogenesisen_US
dc.subjectCanceren_US
dc.subjectHistone deacetylasesen_US
dc.subjectMetabolismen_US
dc.subjectMetastasisen_US
dc.subjectStemness potentialen_US
dc.titleDifferential molecular mechanistic behavior of HDACs in cancer progressionen_US
dc.title.journalMedical Oncologyen_US
dc.typeReviewen_US
dc.type.accesstypeClosed Accessen_US

Files